Literature DB >> 2444649

Purification and characterization of human skin mast cells. Evidence for human mast cell heterogeneity.

I D Lawrence1, J A Warner, V L Cohan, W C Hubbard, A Kagey-Sobotka, L M Lichtenstein.   

Abstract

Our previous studies of human lung and intestinal mast cells failed to show the heterogeneity found among mast cells in murine species. Recently, we and others have developed techniques for the enzymatic dispersion of human neonatal skin mast cells. In addition, we are now able to make single cell suspensions of mast cells from adult skin and to purify these cells to near homogeneity. Comparative studies of mast cells from these several sources have uncovered several major differences among them. Adult and neonatal skin mast cells themselves differ in that the former are 10-fold less sensitive to goat anti-human IgE, with maximal release occurring at 3.0 and 0.3 microgram/ml, respectively. Skin mast cells also differ in optimal temperature for release: adult mast cells respond maximally at 23 to 30 degrees C and neonatal cells at 37 degrees C. Skin mast cells from both sources are dramatically different from lung and intestinal mast cells in two aspects. First, skin mast cells are quite responsive to several stimuli--morphine sulfate (10(-4) to 10(-6) M), substance P (10(-5) to 10(-7) M), compound 48/80 (10 to 0.1 microgram/ml), f-Met peptide (10(-6) M), and C5a (10(-8) M)--to which the other mast cells fail to respond. Second, although stimulated skin mast cells produce prostaglandin D2, little leikotriene C4, if any, is generated, unlike lung or intestinal mast cells. These differences in inflammatory potential among human mast cells from various sites have important implications for the management of allergic and inflammatory responses.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2444649

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  33 in total

1.  Substance P as a potent stimulator of sneeze responses in experimental allergic rhinitis of guinea pigs.

Authors:  T Imamura; T Kambara
Journal:  Agents Actions       Date:  1992-11

Review 2.  Tryptase and chymase, markers of distinct types of human mast cells.

Authors:  S S Craig; L B Schwartz
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

3.  Differential expression of cell surface integrins on human mast cells and human basophils.

Authors:  W R Sperr; H Agis; K Czerwenka; W Klepetko; E Kubista; G Boltz-Nitulescu; K Lechner; P Valent
Journal:  Ann Hematol       Date:  1992-07       Impact factor: 3.673

Review 4.  Upper airways reactions to cold air.

Authors:  Alvaro A Cruz; Alkis Togias
Journal:  Curr Allergy Asthma Rep       Date:  2008-04       Impact factor: 4.806

Review 5.  IgE-dependent signaling as a therapeutic target for allergies.

Authors:  Donald W MacGlashan
Journal:  Trends Pharmacol Sci       Date:  2012-06-30       Impact factor: 14.819

6.  Human mast cell carboxypeptidase. Purification and characterization.

Authors:  S M Goldstein; C E Kaempfer; J T Kealey; B U Wintroub
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

7.  Lack of crucial role of mast cells in pathogenesis of experimental colitis in mice.

Authors:  A Minocha; C Thomas; R Omar
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

8.  Differential response of human basophils and mast cells to recombinant chemokines.

Authors:  W Füreder; H Agis; H Semper; F Keil; U Maier; M R Müller; K Czerwenka; H Höfler; K Lechner; P Valent
Journal:  Ann Hematol       Date:  1995-05       Impact factor: 3.673

9.  Novel six-week protocol for generating functional human connective tissue-type (MCTC) mast cells from buffy coats.

Authors:  Issan Yee San Tam; Chun Wai Ng; See-Ying Tam; Hang Yung Alaster Lau
Journal:  Inflamm Res       Date:  2016-09-15       Impact factor: 4.575

10.  Cultured human synovial fibroblasts rapidly metabolize kinins and neuropeptides.

Authors:  J M Bathon; D Proud; S Mizutani; P E Ward
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.